- Conditions
- Hypertriglyceridemia
- Interventions
- CaPre, Placebo
- Drug
- Lead sponsor
- Grace Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertriglyceridemia
- Interventions
- CaPre, Placebo
- Drug
- Lead sponsor
- Grace Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
- Conditions
- Severe Hypertriglyceridemia (sHTG)
- Interventions
- evinacumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Boca Raton, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more
- Conditions
- Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
- Interventions
- Plozasiran
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 15 Years and older
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- K-877, Fenofibrate, Placebo (for K-877)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 129
- States / cities
- Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
- Conditions
- Hypertriglyceridemia
- Interventions
- ARI-3037MO, Placebo
- Drug
- Lead sponsor
- Arisaph Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more
- Conditions
- Hypertriglyceridemia
- Interventions
- ISIS apoC-III Rx, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Farmville, North Carolina • Greenville, North Carolina • Kinston, North Carolina + 1 more
- Conditions
- Hyperlipidemias, Hypertriglyceridemia, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
- Interventions
- CAT-2003, Placebo
- Drug
- Lead sponsor
- Catabasis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Miami, Florida • Indianapolis, Indiana • Auburn, Maine + 1 more